Cargando…
IL-6–based mortality risk model for hospitalized patients with COVID-19
BACKGROUND: Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. OBJECTIVE: Our aim was to develop a model able to predict the risk of fat...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375283/ https://www.ncbi.nlm.nih.gov/pubmed/32710975 http://dx.doi.org/10.1016/j.jaci.2020.07.009 |
_version_ | 1783561850892320768 |
---|---|
author | Laguna-Goya, Rocio Utrero-Rico, Alberto Talayero, Paloma Lasa-Lazaro, Maria Ramirez-Fernandez, Angel Naranjo, Laura Segura-Tudela, Alejandro Cabrera-Marante, Oscar Rodriguez de Frias, Edgar Garcia-Garcia, Rocio Fernández-Ruiz, Mario Aguado, Jose Maria Martinez-Lopez, Joaquin Lopez, Elena Ana Catalan, Mercedes Serrano, Antonio Paz-Artal, Estela |
author_facet | Laguna-Goya, Rocio Utrero-Rico, Alberto Talayero, Paloma Lasa-Lazaro, Maria Ramirez-Fernandez, Angel Naranjo, Laura Segura-Tudela, Alejandro Cabrera-Marante, Oscar Rodriguez de Frias, Edgar Garcia-Garcia, Rocio Fernández-Ruiz, Mario Aguado, Jose Maria Martinez-Lopez, Joaquin Lopez, Elena Ana Catalan, Mercedes Serrano, Antonio Paz-Artal, Estela |
author_sort | Laguna-Goya, Rocio |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. OBJECTIVE: Our aim was to develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be used easily at the time of patients' arrival at the hospital. METHODS: We constructed a prospective cohort with 611 adult patients in whom COVID-19 was diagnosed between March 10 and April 12, 2020, in a tertiary hospital in Madrid, Spain. The analysis included 501 patients who had been discharged or had died by April 20, 2020. The capacity of several biomarkers, measured at the beginning of hospitalization, to predict mortality was assessed individually. Those biomarkers that independently contributed to improve mortality prediction were included in a multivariable risk model. RESULTS: High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, d-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio were all predictive of mortality (area under the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of peripheral blood oxygen saturation to fraction of inspired oxygen (SpO(2)/FiO(2)). A multivariable mortality risk model including the SpO(2)/FiO(2) ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age was developed and showed high accuracy for the prediction of fatal outcome (area under the curve 0.94). The optimal cutoff reliably classified patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.89 specificity. CONCLUSION: This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making. |
format | Online Article Text |
id | pubmed-7375283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73752832020-07-23 IL-6–based mortality risk model for hospitalized patients with COVID-19 Laguna-Goya, Rocio Utrero-Rico, Alberto Talayero, Paloma Lasa-Lazaro, Maria Ramirez-Fernandez, Angel Naranjo, Laura Segura-Tudela, Alejandro Cabrera-Marante, Oscar Rodriguez de Frias, Edgar Garcia-Garcia, Rocio Fernández-Ruiz, Mario Aguado, Jose Maria Martinez-Lopez, Joaquin Lopez, Elena Ana Catalan, Mercedes Serrano, Antonio Paz-Artal, Estela J Allergy Clin Immunol Covid-19 BACKGROUND: Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. OBJECTIVE: Our aim was to develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be used easily at the time of patients' arrival at the hospital. METHODS: We constructed a prospective cohort with 611 adult patients in whom COVID-19 was diagnosed between March 10 and April 12, 2020, in a tertiary hospital in Madrid, Spain. The analysis included 501 patients who had been discharged or had died by April 20, 2020. The capacity of several biomarkers, measured at the beginning of hospitalization, to predict mortality was assessed individually. Those biomarkers that independently contributed to improve mortality prediction were included in a multivariable risk model. RESULTS: High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, d-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio were all predictive of mortality (area under the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of peripheral blood oxygen saturation to fraction of inspired oxygen (SpO(2)/FiO(2)). A multivariable mortality risk model including the SpO(2)/FiO(2) ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age was developed and showed high accuracy for the prediction of fatal outcome (area under the curve 0.94). The optimal cutoff reliably classified patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.89 specificity. CONCLUSION: This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2020-10 2020-07-22 /pmc/articles/PMC7375283/ /pubmed/32710975 http://dx.doi.org/10.1016/j.jaci.2020.07.009 Text en © 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-19 Laguna-Goya, Rocio Utrero-Rico, Alberto Talayero, Paloma Lasa-Lazaro, Maria Ramirez-Fernandez, Angel Naranjo, Laura Segura-Tudela, Alejandro Cabrera-Marante, Oscar Rodriguez de Frias, Edgar Garcia-Garcia, Rocio Fernández-Ruiz, Mario Aguado, Jose Maria Martinez-Lopez, Joaquin Lopez, Elena Ana Catalan, Mercedes Serrano, Antonio Paz-Artal, Estela IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title | IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title_full | IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title_fullStr | IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title_full_unstemmed | IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title_short | IL-6–based mortality risk model for hospitalized patients with COVID-19 |
title_sort | il-6–based mortality risk model for hospitalized patients with covid-19 |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375283/ https://www.ncbi.nlm.nih.gov/pubmed/32710975 http://dx.doi.org/10.1016/j.jaci.2020.07.009 |
work_keys_str_mv | AT lagunagoyarocio il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT utreroricoalberto il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT talayeropaloma il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT lasalazaromaria il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT ramirezfernandezangel il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT naranjolaura il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT seguratudelaalejandro il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT cabreramaranteoscar il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT rodriguezdefriasedgar il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT garciagarciarocio il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT fernandezruizmario il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT aguadojosemaria il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT martinezlopezjoaquin il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT lopezelenaana il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT catalanmercedes il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT serranoantonio il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 AT pazartalestela il6basedmortalityriskmodelforhospitalizedpatientswithcovid19 |